Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel in Symptomatic Polycystic Liver Disease
2010-024604-10Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in Polycystic liver disease (PLD), sponsored by UZ Leuven. Primary endpoints: Reduction of total liver volume at 6 months, Reduction of total liver volume at 12 months and 1 more. Started Jan 2011; status: completed.
02
Drugs
lanreotide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on 2010-024604-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024604-10.